Author | Vasconcelos, Larissa de Carvalho Medrado | |
Author | Leony, Leonardo Maia | |
Author | Camelier, Aquiles Assunção | |
Author | Meireles, André Costa | |
Author | Oliveira Júnior, AndréLuiz Freitas de | |
Author | Bandeira, Antônio Carlos | |
Author | Macedo, Yasmin Santos Freitas | |
Author | Duarte, Alan Oliveira | |
Author | Van Voorhis, Wesley | |
Author | Siqueira, Isadora Cristina de | |
Author | Santos, Fred Luciano Neves | |
Access date | 2024-02-20T15:07:39Z | |
Available date | 2024-02-20T15:07:39Z | |
Document date | 2024 | |
Citation | VASCONCELOS, Larissa de Carvalho Medrado et al. Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19. IJID Regions, v. 10, p. 1–8, 2024. | en_US |
ISSN | 2772-7076 | en_US |
URI | https://www.arca.fiocruz.br/handle/icict/62680 | |
Sponsorship | Coordenação de Aperfeiçoamento de Pessoal de Nível Superior do Brasil (CAPES).
Conselho Nacional de Desenvolvimento Científico e Tecnológico-Brasil (CNPq).
National Institutes of Health USA. | en_US |
Language | eng | en_US |
Publisher | Elsevier | en_US |
Rights | open access | en_US |
Subject in Portuguese | SARS-CoV-2 | en_US |
Subject in Portuguese | Sorodiagnóstico | en_US |
Subject in Portuguese | Proteína RBD recombinante | en_US |
Subject in Portuguese | Detecção de anticorpos | en_US |
Subject in Portuguese | Desempenho de diagnóstico | en_US |
Title | Usefulness of receptor binding domain protein-based serodiagnosis of COVID-19 | en_US |
Type | Article | en_US |
DOI | 10.1016/j.ijregi.2023.11.001 | |
Abstract | Objectives: This study evaluated the performance of recombinant receptor binding domain (RBD) protein-based enzyme-linked immunosorbent assays (RBD-ELISAs) for detecting anti-SARS-CoV-2 immunoglobulin (Ig) G and IgM antibodies. Methods: In this study, 705 sera from SARS-CoV-2-infected individuals and 315 sera from healthy individuals were analyzed. Results: The RBD-ELISA IgG exhibited high specificity (99.1%) and moderate sensitivity (48.0%), with an overall diagnostic accuracy of 73.5%. RBD-ELISA IgM demonstrated specificity at 94.6% and sensitivity at 51.1%, with an accuracy of 72.8%. Both assays displayed improved performance when analyzing samples collected 15-21 days post-symptom onset, achieving sensitivity and accuracy exceeding 88% and 90%, respectively. Combining RBD-ELISA IgG and IgM in parallel analysis enhanced sensitivity to 98.6% and accuracy to 96.2%. Comparing these RBD-ELISAs with commercially available tests, the study found overlapping sensitivity and similar specificity values. Notably, the combined RBD-ELISA IgG and IgM showed superior performance. Cross-reactivity analysis revealed low false-positive rates (4.4% for IgG, 3.7% for IgM), primarily with viral infections. Conclusion: This research underscores the potential of RBD-based ELISAs for COVID-19 diagnosis, especially when assessing samples collected 15-21 days post-symptom onset and utilizing a parallel testing approach. The RBD protein's immunogenicity and specificity make it a valuable tool for serodiagnosis, offering an alternative to polymerase chain reaction-based methods, particularly in resource-limited settings. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil. | en_US |
Affilliation | Hospital Aliança D’Or. Salvador, BA, Brasil / Escola Bahiana de Medicina e Saúde Pública. Salvador, BA, Brasil / Universidade do Estado da Bahia. Salvador, BA, Brasil. | en_US |
Affilliation | Hospital Aliança D’Or. Salvador, BA, Brasil. | en_US |
Affilliation | Hospital Aliança D’Or. Salvador, BA, Brasil. | en_US |
Affilliation | Hospital Aeroporto. Lauro de Freitas, BA, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Experimental. Salvador, BA, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Experimental. Salvador, BA, Brasil. | en_US |
Affilliation | Department of Medicine. University of Washington. Seattle, USA. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Patologia Experimental. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Programa Translacional Integrado em Doença de Chagas da FIOCRUZ. Rio de Janeiro, RJ, Brasil. | en_US |
Affilliation | Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório Avançado de Saúde Pública. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Programa Translacional Integrado em Doença de Chagas da FIOCRUZ. Rio de Janeiro, RJ, Brasil. | en_US |
Subject | SARS-CoV-2 | en_US |
Subject | Serodiagnosis | en_US |
Subject | Recombinant RBD protein | en_US |
Subject | Antibody detection | en_US |
Subject | Diagnostic performance | en_US |
DeCS | SARS-CoV-2 | en_US |
DeCS | Teste Sorológico para COVID-19 | en_US |
DeCS | Proteínas Recombinantes | en_US |
DeCS | Anticorpos | en_US |
DeCS | Diagnóstico | en_US |